Profound Medical (TSE:PRN) Announces Earnings Results

Profound Medical (TSE:PRN) released its earnings results on Thursday. The company reported C$0.37 EPS for the quarter, FiscalAI reports. The firm had revenue of C$8.20 million for the quarter. Profound Medical had a negative net margin of 287.94% and a negative return on equity of 86.83%.

Profound Medical Price Performance

Shares of TSE PRN traded down C$2.92 during mid-day trading on Friday, reaching C$7.08. 130,472 shares of the company traded hands, compared to its average volume of 18,355. The firm has a market cap of C$256.95 million, a PE ratio of -5.36 and a beta of 1.10. The stock has a fifty day simple moving average of C$10.12 and a 200-day simple moving average of C$8.72. Profound Medical has a fifty-two week low of C$5.23 and a fifty-two week high of C$12.40. The company has a debt-to-equity ratio of 14.80, a current ratio of 4.18 and a quick ratio of 14.98.

Insider Activity at Profound Medical

In related news, insider Thomas Michael Tamberrino bought 13,908 shares of Profound Medical stock in a transaction that occurred on Tuesday, December 23rd. The stock was purchased at an average cost of C$9.91 per share, for a total transaction of C$137,828.28. Following the acquisition, the insider owned 39,241 shares in the company, valued at C$388,878.31. This trade represents a 54.90% increase in their ownership of the stock. Corporate insiders own 8.62% of the company’s stock.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.